Tarsus Acquires Alkeus for $450 Million, Taking Over Phase 3 Oral Drug for Stargardt Disease

For patients with Stargardt disease, central vision gradually disappears, yet there has long been no approved therapy capable of slowing disease progression. Now, late-stage drug development for this rare inherited retinal disease has also become the centerpiece of a major ophthalmology acquisition: Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals for approximately $450 million in upfront consideration, gaining its oral drug candidate gildeuretinol acetate (ALK-001).

The deal’s primary value hinges on the ongoing enrollment of the Phase 3 NORTHSTAR trial. This randomized, placebo-controlled, double-blind study is expected to enroll approximately 230 patients aged 8 to 45, who will take gildeuretinol acetate or placebo daily for a 24-month treatment period. Patients must have typical autosomal recessive Stargardt disease and carry at least one pathogenic ABCA4 gene variant.

Stargardt disease usually results from abnormal ABCA4 function, which causes toxic byproducts of vitamin A metabolism to accumulate in the retina, gradually damaging cells in the macula responsible for central vision. Gildeuretinol is a modified form of vitamin A designed not to block the visual cycle, but to reduce the likelihood that vitamin A will form toxic dimers and related byproducts, thereby slowing retinal atrophy.

NORTHSTAR is expected to be conducted at approximately 55 trial sites across more than 11 countries. The primary endpoint is not a short-term change on a standard eye chart, but a comparison between the treatment and placebo groups of the annual expansion rate of retinal atrophy lesions from months 6 to 24; preservation of low-luminance visual acuity is listed as an important secondary assessment. This design reflects the disease’s slow progression and also means that interpreting efficacy requires long-term imaging follow-up.

According to the ClinicalTrials.gov registration, the trial is expected to complete its primary endpoint assessment in October 2029, while the overall study may continue until December 2030. For Tarsus, the $450 million is buying an asset that has entered a pivotal trial but remains several years away from a potential marketing application; whether the transaction can translate into a new product will depend on whether the difference in lesion expansion is both statistically and clinically meaningful.

Alkeus said that more than 400 patients have received gildeuretinol in previous studies, and that the drug has also received Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the U.S. Food and Drug Administration. However, these designations are intended to accelerate development and review and do not constitute confirmation of efficacy or marketing approval; currently available public data are also insufficient to determine the Phase 3 outcome based solely on early-stage studies.

The acquisition therefore represents a bet on both the scientific hypothesis and execution capabilities: if reducing toxic vitamin A byproducts can indeed slow atrophy, an oral therapy could provide patients with an option distinct from intraocular injections or gene therapy; if the imaging endpoint does not translate into perceptible preservation of vision, or if long-term safety issues arise, the substantial upfront investment will come under pressure. Until the Phase 3 data are released, the size of the deal demonstrates Tarsus’s confidence in this pathway, not that efficacy has been proven.